N/A N=35 Neural Bases of Cognitive Rehabilitation for Brain Injury
Brain Injury
Primary: Change From Baseline on a Composite Measure (Z-score) of Attention, Working Memory, and Executive Functions — 0.26; .01 Change to Z (composite) score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=484 Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)
Non-erosive Gastroesophageal Reflux Disease
Primary: Percentage of Days Without Symptoms of Heartburn — 61.50; 72.55 percentage of days — p=0.0643
N/A N=248 Postoperative Management for Degenerative Spinal Conditions
Spinal Degenerative Disorder
Primary: Oswestry Disability Index (ODI) — 43.6; 45.46; 31.31; 31.19 units on a scale
N/A N=24 Human Comedogenicity Test
Comedogenicity
Primary: Microcomedone Score of Follicular Biopsies — 0.84; 0.97 microcomedone score — p=0.274
N/A N=22 Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
Hypoplastic Left Heart Syndrome
Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days
Phase 2 N=13 Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance
Stroke · Hemispatial Neglect
Primary: Performance on Tests of Hemispatial Neglect and Sustained Attention — 31.15; 26.15 Number of targets found — p=0.013
N/A N=72 Safety And Efficacy Of Rifabutin In HIV Patients
Non-tuberculous Mycobacterial Diseases · Tuberculosis · Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
Primary: Number of Patients With Adverse Drug Reactions in This Surveillance — 16; 7 Participants
Phase 1 N=153 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Renal Cell Carcinoma · Clear-cell Metastatic Renal Cell Carcinoma
Primary: Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation — 3; 16; 13; 29 participants
Phase 4 N=48 Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
HIV-1 Infection
Primary: Proportion of Patients With 50% Reduction of Fibrosis in Lymphatic Tissue. — 0; 0; 0; 0 participants — p=1
Phase 3 N=347 European Phase III Study of APD421 in PONV
PONV
Primary: Complete Response (no Emesis, Significant Nausea or Rescue Medication) — 95; 83 Participants — p=0.093
Phase 1 N=103 Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Primary: Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1 — 0; 0; 1; 2…
Phase 2 N=46 A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Safety and Tolerability of IMO-8400 Compared With Placebo — 6; 6; 6; 5 adverse events — p=0.06
N/A N=58 Evaluation of Triathlon - A New Total Knee Prosthesis System - Roentgen Stereophotogrammetric Analysis (RSA) Triathlon CR vs. PS
Arthroplasty, Replacement, Knee
Primary: Assessment of Fixation and Stability of the Triathlon Total Knee Prosthesis by Roentgen Stereophotogrammetric Analysis (RSA) — 0.68; 0.79 mm
Phase 2 N=346 Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants
Pneumococcal Disease
Primary: Adult and Toddler Subjects Experiencing Local and Systemic Reactogenicity, by Severity — 0; 0; 5; 6 Participants
Phase 2 N=30 Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose (FPG) — 5.8; 5.5 mmol/L — p=0.004